Compensation for Cures: Why We Should Pay a Premium for Participation in ‘Challenge Studies’

6 Pages Posted: 30 Apr 2020

See all articles by Jonathan Anomaly

Jonathan Anomaly

Duke University

Julian Savulescu

University of Oxford - Uehiro Centre for Practical Ethics

Date Written: September 2019

Abstract

Antibiotic resistance is one of the most pressing public health problems humanity faces. Research into new classes of antibiotics and new kinds of treatments – including risky experimental treatments such as phage therapy and vaccines – is an important part of improving our ability to treat infectious diseases. In order to aid this research, we will argue that we should permit researchers to pay people any amount of money to compensate for the risks of participating in clinical trials, including ‘challenge studies’ that involve deliberately infecting patients. We think that standard worries about paying for participation in risky research are reducible to concerns that can be addressed with the right screening mechanisms.

Keywords: antibiotic resistance, antibiotics, challenge studies, consent, phage therapy

Suggested Citation

Anomaly, Jonathan and Savulescu, Julian, Compensation for Cures: Why We Should Pay a Premium for Participation in ‘Challenge Studies’ (September 2019). Bioethics, Vol. 33, Issue 7, pp. 792-797, 2019, Available at SSRN: https://ssrn.com/abstract=3588716 or http://dx.doi.org/10.1111/bioe.12596

Jonathan Anomaly (Contact Author)

Duke University ( email )

100 Fuqua Drive
Durham, NC 27708-0204
United States

Julian Savulescu

University of Oxford - Uehiro Centre for Practical Ethics ( email )

10 Merton Street
Oxford OX1 3JP
United Kingdom
+44 1865 276926 (Phone)
+44 1865 276932 (Fax)

HOME PAGE: http://www.practicalethics.ox.ac.uk/juliansavulescu.html

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
0
Abstract Views
71
PlumX Metrics